ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) Director Barry Simon sold 23,033 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $7.18, for a total transaction of $165,376.94. Following the completion of the transaction, the director owned 2,827,788 shares of the company’s stock, valued at $20,303,517.84. This trade represents a 0.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ImmunityBio Price Performance
Shares of ImmunityBio stock opened at $6.92 on Friday. The company has a 50-day moving average of $7.56 and a 200 day moving average of $5.95. The firm has a market cap of $7.25 billion, a price-to-earnings ratio of -8.14 and a beta of 0.03. ImmunityBio, Inc. has a 1 year low of $1.95 and a 1 year high of $12.43.
ImmunityBio (NASDAQ:IBRX – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The company had revenue of $44.21 million for the quarter, compared to the consensus estimate of $43.07 million. On average, equities analysts anticipate that ImmunityBio, Inc. will post -0.31 EPS for the current year.
Analysts Set New Price Targets
Read Our Latest Report on ImmunityBio
Institutional Trading of ImmunityBio
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vestor Capital LLC bought a new stake in ImmunityBio during the 1st quarter valued at about $88,000. Arete Wealth Advisors LLC bought a new stake in ImmunityBio during the 1st quarter valued at about $4,500,000. Norris Financial Group LLC bought a new stake in ImmunityBio during the 1st quarter valued at about $108,000. Western Wealth Management LLC purchased a new stake in shares of ImmunityBio during the 1st quarter valued at about $44,000. Finally, Bank of America Corp DE boosted its holdings in shares of ImmunityBio by 2.7% during the 1st quarter. Bank of America Corp DE now owns 2,447,843 shares of the company’s stock valued at $18,775,000 after acquiring an additional 65,340 shares during the last quarter. 8.58% of the stock is currently owned by institutional investors.
ImmunityBio Company Profile
ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.
Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.
Featured Articles
- Five stocks we like better than ImmunityBio
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
